Latest Security News

Redcastle Resources Limited has resumed trading on the ASX following key announcements about a joint venture farm-out, a strategic placement, and a major gold project acquisition.

Redcastle Resources has partnered with BML Ventures to fast-track gold production at key deposits while massively expanding its Eastern Goldfields footprint through a strategic tenement acquisition.

Genetic Technologies Limited reports a 36% increase in half-year losses amid voluntary administration, followed by a recapitalisation and sale of core assets. The company pivots towards new financial services acquisitions under fresh leadership.

Saunders International reported a modest revenue dip and sharp profit decline in FY2025, offset by a transformative acquisition that expands its water infrastructure footprint and doubles its project pipeline.

Magnetite Mines has launched a $2.65 million renounceable rights issue with increased underwriting support, following promising rare earth mineralisation findings at its Ironback Hill Project.

Vicinity Centres confirms its distribution reinvestment plan will apply to the FY25 final distribution, offering investors a 1% discount on new securities issued under the plan.

Marquee Resources has successfully closed an oversubscribed $2.51 million placement, underscoring strong investor confidence as it prepares for the next phase of drilling at its Mt Clement Antimony Project.

WOTSO’s FY2025 results reveal an 11% revenue decline but a significantly reduced net loss, alongside a raised distribution payout, signaling cautious optimism amid market challenges.

Invion Limited secures a pivotal FDA Orphan Drug Designation for its lead candidate INV043, targeting anal cancer with promising preclinical results and a fast-tracked development path.

Saunders International reported a sharp 77.9% drop in net profit for FY2025, even as revenue dipped only slightly by 0.7%. The company declared a final dividend, signaling cautious optimism amid earnings pressure.

Invion Limited has disclosed that the US FDA granted Orphan Drug Designation for its lead cancer drug candidate INV043, explaining recent unusual trading activity in its shares. The company confirmed it was unaware of the FDA decision prior to its public release and has now complied with continuous disclosure rules.

Vicinity Centres reported a doubling of net profit and delivered funds from operations at the top of guidance, underpinned by strategic acquisitions and strong portfolio performance.